VC Spotlight: Newpath Partners
Boston doesn't just nurture academics, it manufactures revolutions. From gene editing corridors to Broad Institute labs stacked with Nobel ambitions, this city births breakthroughs that redraw medicine's map. In 2018, Thomas J. Cahill, M.D., Ph.D. and Daniel Yadegar, M.D. launched Newpath Partners with a bet that venture capital could do more than fund companies, it could co-found them. This wasn't a firm chasing exits. It was a company-builder, engineered to align scientists, operators, and investors from day one.
Dr. Cahill trained under Nobel laureate Robert Lefkowitz at Duke, added an M.S. in Chemistry from Stanford, then shifted from medicine to investing at Raptor Group. But Newpath Partners demanded something different: conviction before product. Dr. Yadegar, Harvard and Cornell-trained, triple-board-certified, brought the clinical precision. Together they built a model that treats science as the raw material and alignment as the architecture.
The team is stacked to deliver on that model. Greg McGraw, CFO since 2023, brings Third Rock Ventures discipline. Prateek Katti, M.D., Ph.D., combines NIH research depth with McKinsey rigor, dissecting hypotheses with precision. Tom M. Thomas, Ph.D. adds computational firepower, parsing data streams for signals the market hasn't priced in. This is venture as science translation, not trend chasing.
The portfolio speaks for itself. Prime Medicine raised $315 million to advance "search and replace" gene editing. Chroma Medicine secured $125 million to pioneer epigenetic editing. Exo Therapeutics landed $78 million for allosteric enzyme drug discovery. Kojin Therapeutics closed $60 million to attack cancer and fibrosis. Magnet Biomedicine drew $50 million to design molecular glues. Stealth players like Myeloid Therapeutics, Nvelop Therapeutics, Autobahn Therapeutics, and Aera are loaded in the chamber. Metsera already hit the public markets in January 2025.
Newpath Partners's edge is conviction. Pre-product, pre-proof, they partner with academic pioneers like David Liu, Ben Cravatt, and Siddhartha Mukherjee to shape ventures from the first experiment. Incentive structures align founders, operators, and employees in a shared outcome. And when the pandemic hit, Dr. Cahill's Scientists to Stop COVID-19 coalition proved the ethos: lead with science, remove conflicts, deliver impact.
This is not a check-writing firm. It is a co-building engine, pulling discoveries from labs and converting them into therapies the world needs. And the companies forged through this model are actively hiring across R&D, clinical development, and commercial roles.
Prime Medicine — https://primemedicine.com/careers/
Chroma Medicine — https://job-boards.greenhouse.io/chromamedicine
Follow this firm. Study their founders. Track their plays.
Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing, together, we’re pushing boundaries. Proud to be building the future with you.
Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.
If engineering peace of mind is what you crave, Vention is your zen.